Protagonist Therapeutics Market Sentiment

Protagonist Therapeutics Inc

PTGXNASDAQ

Trade with Public

$148.80

2.721.86%

近くで: Sep 2, 5:00 PM EST

$148.80

2.721.86%

プレマーケット: 7:00 AM EST

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Protagonist Therapeutics Market Sentiment

Market sentiment signals for Protagonist Therapeutics (PTGX): analyst consensus, short interest, options flow and insider activity.

Key Signals

Analyst Consensus▲ Buy

Short Interest▼ 14.0% short float

Options Flow— N/A

Insider Activity— Neutral (30d)

Analyst Consensus

Buy

18 analysts

Options Flow (P/C)

—

Avg Consensus PT

$129

-13.5%

Highest Price Target

$190

+27.7%

BMO Capital

Lowest Price Target

$38

-74.5%

Goldman Sachs

Short Interest

14.0%

Rising — Bearish

Insider Activity (30d)

Neutral

Short Interest — % of Float

Recent Analyst Actions

Date	Firm	Analyst & Accuracy	Upside / Downside	PT Change	Action	Rating
Sep 1, 2026	Barclays	Etzer Darout—	+21.0%	$153 → $180	Maintained	Overweight
Sep 1, 2026	BMO Capital	Etzer Darout—	+27.7%	$178 → $190	Maintained	Outperform
Aug 31, 2026	Citigroup	Geoff Meacham—	+22.3%	$175 → $182	Maintained	Buy
Aug 31, 2026	HC Wainwright & Co.	Douglas Tsao—	+14.2%	$167 → $170	Maintained	Buy
Aug 17, 2026	BMO Capital	Etzer Darout—	+19.6%	$112 → $178	Maintained	Outperform
Aug 10, 2026	Truist Securities	Srikripa Devarakonda—	+14.2%	$145 → $170	Maintained	Buy
Aug 10, 2026	Wedbush	Yun Zhong—	+16.3%	$118 → $173	Maintained	Outperform
Aug 10, 2026	Goldman Sachs	Richard Law—	+25.0%	$110 → $186	Upgrade	Neutral→Buy
Aug 6, 2026	Citigroup	Geoff Meacham—	+17.6%	$130 → $175	Maintained	Buy
Aug 6, 2026	Barclays	Etzer Darout—	+2.8%	$151 → $153	Maintained	Overweight
Jul 14, 2026	Barclays	Etzer Darout—	+1.5%	$119 → $151	Maintained	Overweight
Jul 7, 2026	Truist Securities	Srikripa Devarakonda—	-2.6%	$121 → $145	Maintained	Buy
May 10, 2026	Citigroup	Geoff Meacham—	-12.6%	$125 → $130	Maintained	Buy
May 6, 2026	Citizens	Jonathan Wolleben—	-7.9%	$120 → $137	Maintained	Market Outperform
May 6, 2026	Wedbush	Yun Zhong—	-20.7%	$112 → $118	Maintained	Outperform
Apr 15, 2026	Truist Securities	Srikripa Devarakonda—	-18.7%	$110 → $121	Maintained	Buy
Apr 7, 2026	Clear Street	Kaveri Pohlman—	-22.0%	$104 → $116	Maintained	Buy
Mar 19, 2026	Leerink Partners	Faisal Khurshid—	-26.1%	$107 → $110	Maintained	Outperform
Mar 19, 2026	JP Morgan	Brian Cheng—	-28.8%	$95 → $106	Maintained	Overweight
Mar 19, 2026	Citigroup	Geoff Meacham—	-16.0%	$115 → $125	Maintained	Buy
Mar 19, 2026	Barclays	Etzer Darout—	-20.0%	$113 → $119	Maintained	Overweight
Mar 3, 2026	Goldman Sachs	Richard Law—	-36.2%	$65 → $95	Maintained	Neutral
Feb 26, 2026	TD Cowen	Tara Bancroft—	-32.8%	$90 → $100	Maintained	Buy
Feb 26, 2026	Barclays	Etzer Darout—	-24.1%	$108 → $113	Maintained	Overweight
Feb 26, 2026	Citizens	Jonathan Wolleben—	-24.7%	$102 → $112	Maintained	Market Outperform